Search

Genetic, transcriptional, and clinical heterogeneity of disease has remained to be a prominent obstacle to the development of a targeted therapeutic approach against TNBC. So far, based on tumor size, lymph node status, and histologic features TNBC subtypes were stratified. Insights into inter and intratumoral heterogeneity of TNBC were gained by next-generation sequencing, genomic, transcriptomic, proteomic, and clinicopathological characterization. To depict tumor response to neoadjuvant chemotherapy, radiological characterization may also a play significant role. Biomarkers for subtyping TNBC were highly needed to depict the survival outcome. This chapter discussed the available and possible molecular and pathological diagnostic approaches to TNBC. Furthermore, the integration of morphological and genomic data may emerge as a promising approach for the identification of new therapeutic and prognostic markers to predict the likely outcome of the disease. This chapter aims to highlight the molecular and pathological diagnostic approaches to depict both metastatic and non-metastatic TNBC.&nbsp

95% of anti-cancer agents were associated with the worst pharmaceutical and pharmacokinetic properties including poor targeted cellular uptake, shorter halflife, toxicity, and many more. In this regard, nanotechnology including nanomedicines, nano-carriers, and nanomaterials may emerge as a beneficial tool to facilitate an efficient delivery of therapeutic regimens by adapting active or passive targeting mechanisms. The nanotechnology-based delivery system of phytoconstituents can efficiently battle against recalcitrant TNBC. This chapter highlighted the nanotechnology-based therapeutic approach including smart nanoparticles, cell membrane-coated nanoparticles, and immunological cell-based nano-systems for the treatment of TNBC. Furthermore, the role of nano-soldiers in improving bioavailability and targeted drug delivery was highlighted. Nano conjugates of curcumin, anacardic acid, EGCG, betulinic acid, gambogic acid, and resveratrol were also evaluated to enhance the pharmacokinetic profile, distribution, and the release rate of respective compounds and ultimately their ability to target TNBC.&nbsp